INDOUS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Indo US Bio-Tech Re-Appoints Jagdish Ajudiya As MD
Aug 28 (Reuters) - Indo Us Bio-Tech Ltd INOD.NS:
INDO US BIO-TECH LTD - RE-APPOINTS JAGDISH AJUDIYA AS MANAGING DIRECTOR
Source text: ID:nNSE3QSCgz
Further company coverage: INOD.NS
(([email protected];;))
Aug 28 (Reuters) - Indo Us Bio-Tech Ltd INOD.NS:
INDO US BIO-TECH LTD - RE-APPOINTS JAGDISH AJUDIYA AS MANAGING DIRECTOR
Source text: ID:nNSE3QSCgz
Further company coverage: INOD.NS
(([email protected];;))
Indo Us Bio-Tech Recommendeds Bonus Issue Of Shares In Ratio Of 1:1
July 7 (Reuters) - Indo Us Bio-Tech Ltd INOD.BO:
INDO US BIO-TECH LTD - RECOMMENDED BONUS ISSUE OF SHARES IN RATIO OF 1 SHARE FOR EVERY 1 SHARES HELD
Source text for Eikon: ID:nBSE4jfr8H
Further company coverage: INOD.BO
(([email protected];))
July 7 (Reuters) - Indo Us Bio-Tech Ltd INOD.BO:
INDO US BIO-TECH LTD - RECOMMENDED BONUS ISSUE OF SHARES IN RATIO OF 1 SHARE FOR EVERY 1 SHARES HELD
Source text for Eikon: ID:nBSE4jfr8H
Further company coverage: INOD.BO
(([email protected];))
Indo Us Bio-Tech To Consider To Recommend Issue Of Bonus Shares
June 30 (Reuters) - Indo Us Bio-Tech Ltd INOD.BO:
TO CONSIDER TO RECOMMEND ISSUE OF BONUS SHARES
Source text for Eikon: ID:nBSE1prxJR
Further company coverage: INOD.BO
(([email protected];;))
June 30 (Reuters) - Indo Us Bio-Tech Ltd INOD.BO:
TO CONSIDER TO RECOMMEND ISSUE OF BONUS SHARES
Source text for Eikon: ID:nBSE1prxJR
Further company coverage: INOD.BO
(([email protected];;))
Upcoming Events:
e-Voting
Events:
Dividend
Bonus
Bonus
Dividend
Bonus
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Indo US Bio-Tech do?
Indo US Bio-Tech Limited specializes in breeding, processing, and marketing high-performance agricultural seed varieties under brands like INDO-US 955. They also offer seed testing services.
Who are the competitors of Indo US Bio-Tech?
Indo US Bio-Tech major competitors are Tierra Agrotech, JK Agri Genetics, Eco Friendly Food, Kotyark Industries, Rajputana Biodiesel, Upsurge Seeds Of Agr, Mangalam Seeds. Market Cap of Indo US Bio-Tech is ₹247 Crs. While the median market cap of its peers are ₹203 Crs.
Is Indo US Bio-Tech financially stable compared to its competitors?
Indo US Bio-Tech seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Indo US Bio-Tech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Indo US Bio-Tech latest dividend payout ratio is 3.08% and 3yr average dividend payout ratio is 3.08%
How has Indo US Bio-Tech allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Indo US Bio-Tech balance sheet?
Balance sheet of Indo US Bio-Tech is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Indo US Bio-Tech improving?
Yes, profit is increasing. The profit of Indo US Bio-Tech is ₹17.8 Crs for TTM, ₹16.27 Crs for Mar 2025 and ₹8.25 Crs for Mar 2024.
Is the debt of Indo US Bio-Tech increasing or decreasing?
Yes, The net debt of Indo US Bio-Tech is increasing. Latest net debt of Indo US Bio-Tech is ₹14.35 Crs as of Mar-25. This is greater than Mar-24 when it was ₹12.13 Crs.
Is Indo US Bio-Tech stock expensive?
Indo US Bio-Tech is not expensive. Latest PE of Indo US Bio-Tech is 13.85, while 3 year average PE is 36.82. Also latest EV/EBITDA of Indo US Bio-Tech is 12.63 while 3yr average is 27.06.
Has the share price of Indo US Bio-Tech grown faster than its competition?
Indo US Bio-Tech has given better returns compared to its competitors. Indo US Bio-Tech has grown at ~35.37% over the last 3yrs while peers have grown at a median rate of -7.0%
Is the promoter bullish about Indo US Bio-Tech?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Indo US Bio-Tech is 70.17% and last quarter promoter holding is 70.17%.
Are mutual funds buying/selling Indo US Bio-Tech?
There is Insufficient data to gauge this.